PTCT — PTC THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1070081 ·
Last close
$60.36
Market Cap
$5.04B
52W High
$90.87
52W Low
$58.80
ADV30
1,064,798
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 357,807,000 334,143,000 25,114,000 -51,693,000 3,207,715,000 508,894,000 3,398,924,000
Jun 2026 360,519,000 340,598,000 148,977,000 83,496,000 3,250,477,000 1,049,887,000 3,415,840,000
Mar 2026 272,551,000 244,523,000 45,886,000 -2,809,000 2,869,104,000 833,986,000 3,049,569,000
Dec 2025 164,677,000 157,727,000 -81,624,000 -134,965,000 2,898,767,000 984,648,000 3,104,080,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,503,000
Investing CF
$-471,907,000
Financing CF
$536,004,000
CapEx
$-302,053,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,883,542,000
Inventory
$91,354,000
Receivables
$239,044,000
ST Investments
$1,179,195,000
EBIT TTM
$118,217,000
Pretax Income TTM
$-67,074,000
Interest Exp TTM
$185,291,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,155,554,048
EBITDA
$309,559,008
Free Cash Flow
$159,936,256
Enterprise Value
$5,823,869,952
Total Cash
$2,127,917,952
Total Debt
$2,941,637,120
Shares Out
83,544,284
Trailing EPS
$-0.65
Book Value
$-1.99
ROE
—
ROA
5.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,730,655,000 856,508,000 682,644,000 2,898,767,000 3,104,080,000 -205,313,000 711,196,000
Dec 2024 806,780,000 -146,747,000 -363,295,000 1,705,024,000 2,803,095,000 -1,098,071,000 -107,688,000
Dec 2023 937,822,000 -349,402,000 -626,604,000 1,895,698,000 2,714,253,000 -818,555,000 -158,418,000
Dec 2022 698,801,000 -439,925,000 -559,017,000 1,705,619,000 2,052,705,000 -347,086,000 -356,654,000

TTM Snapshot

Revenues TTM
$1,008,754,000
NetIncome TTM
$-38,382,000
OpCashFlow TTM
—
Assets (Latest)
$3,250,477,000
Forward EPS
$2.37

Max Pain — expiry 2027-01-15

max pain strike: $70.00 · spot: $60.23 · call oi: 11,657 · put oi: 1,101
Expected Move to 2027-01-15: ±$9.35 (15.52%) — implied range $50.88 – $69.58 · ATM straddle on $60.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LQDA Liquidia Corp $5.11B $56.73 —
TVTX Travere Therapeutics, Inc. $4.91B $51.10 —
DNTH Dianthus Therapeutics, Inc. /DE/ $4.90B $86.98 —
ERAS Erasca, Inc. $4.87B $13.89 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —

News headlines (Yahoo Finance, 1h cache)

PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date
2026-11-17 00:14 · Yahoo
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
2026-11-03 12:00 · Yahoo
PTC Therapeutics to Participate in Upcoming Investor Conferences
2026-11-02 13:00 · Yahoo
PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss
2026-10-31 17:12 · Yahoo
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 20:30 · Yahoo
PTC Therapeutics (PTCT) Q3 2026 Earnings Call Transcript
2026-10-30 15:00 · Yahoo
PTC Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-10-30 12:30 · Yahoo
PTC Therapeutics Q3 Earnings Call Highlights
2026-10-30 01:14 · Yahoo
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-10-29 21:00 · Yahoo
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
2026-10-29 20:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.